GEHC GE HealthCare
Steady imaging incumbent with modest margin upside; fairly priced, not a bargain at ~$72.
The story
GE HealthCare is a scaled incumbent in medical imaging, ultrasound, patient monitoring and pharmaceutical diagnostics, with a sticky installed base, a growing service annuity, and a radiopharma and contrast franchise that helps protect it. It is a mature business that has only recently been spun off. Growth is mid-single-digit, and the margin story is self-help: pricing, mix shift toward recurring revenue and new products such as photon-counting CT and theranostics tracers, offset by tariffs and weak China demand. There is room for modest operating margin expansion toward the high teens, not a step change.
Growth of 4% matches the roughly 4% five-year CAGR and an installed-base replacement cycle; terminal growth of 3% sits safely below the 4.99% risk-free rate. The target margin of 16.5% is a bit above the 15-16% historical band, reflecting mix and cost actions but discounted for tariffs and China. Marginal sales-to-capital of 1.4 is above the reported 1.04, which is depressed by spin-off goodwill, because incremental growth needs little capital. Beta of 0.95 sits near the 0.9 medtech anchor, nudged up for leverage of about $5.5B in net debt.
Value drivers
| Revenue growth (Y1) | 4.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 7y |
| Target operating margin | 16.5% |
| Years to target margin | 5 |
| Sales-to-capital | 1.40 |
| Beta | 0.95 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 8.3% |
| Terminal WACC | 8.4% |
Valuation bridge
| PV of explicit FCFF | 12.47B |
| PV of terminal value | 28.07B |
| Equity value | 33.90B |
| ÷ shares → per share | $75.05 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 22.12B | 4.0% | 14.9% | 2.57B | 607.63M | 1.96B | 1.81B |
| 2 | 22.97B | 3.8% | 15.3% | 2.74B | 605.60M | 2.13B | 1.82B |
| 3 | 23.81B | 3.7% | 15.7% | 2.91B | 601.48M | 2.31B | 1.82B |
| 4 | 24.64B | 3.5% | 16.1% | 3.09B | 595.19M | 2.49B | 1.81B |
| 5 | 25.46B | 3.3% | 16.5% | 3.27B | 586.69M | 2.68B | 1.80B |
| 6 | 26.27B | 3.2% | 16.5% | 3.37B | 575.93M | 2.80B | 1.74B |
| 7 | 27.06B | 3.0% | 16.5% | 3.47B | 562.90M | 2.91B | 1.67B |
Key risks
- Tariff costs and China volume-based procurement compress imaging margins
- Hospital capex slowdown or reimbursement pressure delays equipment replacement cycles
- Competitive pressure from Siemens Healthineers and Philips in CT/MR plus execution risk in radiopharma pipeline
Catalysts
- Photon-counting CT and AI-enabled imaging launches driving share gains and pricing
- Pharmaceutical diagnostics growth from new PET tracers (e.g., Flyrcado) and theranostics adoption